{
    "organizations": [],
    "uuid": "d6bcd49b257b35e9874595a6d577c446bc71ffce",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-argenx-to-present-complete-data-fr/brief-argenx-to-present-complete-data-from-phase-2-proof-of-concept-trial-of-efgartigimod-idUSFWN1S105U",
    "ord_in_thread": 0,
    "title": "BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " ARGENX NV:\n* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING\n* EIGHT-WEEK FOLLOW-UP DATA SHOW SEPARATION OF CLINICAL EFFICACY SCORES BETWEEN TREATMENT GROUP AND PLACEBO GROUP THROUGH DURATION OF STUDY\n* TOTAL AND PATHOGENIC IGG REDUCTION CORRELATES WITH DISEASE SCORE IMPROVEMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-24T13:13:00.000+03:00",
    "crawled": "2018-04-25T14:44:58.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "argenx",
        "nv",
        "present",
        "complete",
        "data",
        "phase",
        "trial",
        "efgartigimod",
        "generalized",
        "myasthenia",
        "gravis",
        "american",
        "academy",
        "neurology",
        "aan",
        "annual",
        "meeting",
        "data",
        "show",
        "separation",
        "clinical",
        "efficacy",
        "score",
        "treatment",
        "group",
        "placebo",
        "group",
        "duration",
        "study",
        "total",
        "pathogenic",
        "igg",
        "reduction",
        "correlate",
        "disease",
        "score",
        "improvement",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}